Celularity, a US-based biotech startup, has received an initial clearance from the Food and Drug Administration (FDA) to begin early-stage clinical trials for a potential cell therapy treatment for COVID-19. It will begin an 86-person trial to test the efficacy of its CYNK-001 immunotherapy to treat infected adults. Its cell therapy is derived from stem cells cultivated from human placentas.
Source: TechChurn
